6/27/2007 | CV | MedImmune calls 1% convertibles
|
6/18/2007 | CV | MedImmune closes merger, says 1.375%, 1.625% notes convertible through July 31
|
6/6/2007 | SS | AstraZeneca completes tender offer for MedImmune
|
5/2/2007 | CV | MedImmune says upcoming acquisition makes 1.375%, 1.625% notes convertible
|
4/30/2007 | CV | Market Commentary: Tyco continues gains amid tender offer; MedImmune up ahead of earnings; issuance grows in April
|
4/23/2007 | SS | Market Commentary: MedImmune deal rekindles buzz of biotech buyouts; Genesco gains; Vonage eyed
|
4/23/2007 | CV | Market Commentary: MedImmune surges on buyout; Bausch & Lomb climbs on rumors; AMD, Charming Shoppes launch deals
|
4/23/2007 | SS | AstraZeneca to acquire MedImmune for $58 per share in all-cash transaction
|
4/16/2007 | SS | Icahn withdraws opposition to MedImmune's board nominees now that company is for sale
|
4/16/2007 | SS | Market Commentary: Sallie lags below deal; Quest off; Fremont firms; Innkeepers stock up but convertible slides; Cott up
|
4/13/2007 | SS | Market Commentary: Sallie rides going-private rumor higher; Bally bounces; Calpine climbing; Novastar Financial off
|
4/12/2007 | SS | Market Commentary: Ipsco firms; Med-Immune better; Dow Chemical gains; NovaStar common rises, preferred zooms
|
4/12/2007 | CV | Market Commentary: TriZetto gains in start; MedImmune surges on buyer search; RAIT, Franklin deals seen with subprime risks
|
4/12/2007 | SS | MedImmune to consider strategic alternatives
|
11/6/2006 | BT | MedImmune at neutral by Merrill
|
10/27/2006 | BT | JMP drops MedImmune coverage
|
10/26/2006 | BT | MedImmune third-quarter revenues up 15%, net loss at $72.8 million
|
10/26/2006 | BT | Merrill rates MedImmune neutral
|
9/13/2006 | BT | MedImmune readies for $250 million facility expansion
|
8/28/2006 | BT | MedImmune, Infinity form development, commercialization agreement
|
8/28/2006 | BT | Market Commentary: Discovery Partners up 9% on MedImmune, Infinity pact; EPIX plunges; Sinovac soars; PDL up
|
8/21/2006 | BT | MedImmune files IND for MT103 to treat lymphomas, triggers milestone payment to Micromet
|
8/16/2006 | BT | Bear Stearns keeps MedImmune at outperform
|
8/1/2006 | BT | Bear Stearns maintains MedImmune at outperform
|
7/31/2006 | BT | MedImmune's FluMist submitted to FDA for approval in younger children
|
7/28/2006 | BTCV | MedImmune 1% noteholders opt to put $489.6 million notes in July
|
7/21/2006 | BT | MedImmune, Micromet: BiTE may offer anticancer therapeutic with fewer side effects
|
7/21/2006 | BT | JMP reiterates MedImmune at market perform
|
7/20/2006 | BT | MedImmune reports GAAP net loss of $63 million for second quarter
|
7/20/2006 | BT | Merrill maintains MedImmune at neutral
|
7/18/2006 | BT | MedImmune says FDA requests more FluMist data
|
7/18/2006 | BT | Merrill keeps MedImmune at neutral
|
7/6/2006 | BT | MedImmune's sBLA for production of seasonal influenza vaccines approved by FDA
|
6/30/2006 | BT | MedImmune maintained at neutral by Merrill
|
6/29/2006 | BT | Alexion kept at buy by Merrill
|
6/28/2006 | BTCV | MedImmune greenshoes fully exercised, boosting convertibles sales to $1.15 billion
|
6/27/2006 | CV | Market Commentary: MedImmune, Gilead trade; Vector launches overnight deal; Chesapeake prices
|
6/23/2006 | BT | MedImmune kept at outperform by RBC
|
6/23/2006 | BTCV | New Issue: MedImmune $1 bln convertibles: five year yields 1.375%, seven year yields 1.625%, up 22.5%
|
6/22/2006 | BTCV | S&P gives MedImmune convertibles BBB
|
6/22/2006 | CV | Market Commentary: MedImmune on deck, no gray seen; Equity Office Properties, American Medical new deals seen higher
|
6/22/2006 | BTCV | MedImmune prices $1 billion convertibles: 5-years yield 1.375%, 7-years yield 1.625%, both up 22.5%
|
6/22/2006 | BT | Market Commentary: Gene Logic plunges 36%; ISTA off; MedImmune convertible on deck; American Medical issues higher
|
6/21/2006 | BT | Market Commentary: Cell Therapeutics gains on equity financing; Arena higher on data; MedImmune airs $1 billion bond deal
|
6/21/2006 | CV | Market Commentary: Teva sinks outright, holds up dollar neutral; Group 1 re-offered; $2 billion new deals seen pricing Thursday
|
6/21/2006 | BTCV | MedImmune launches $1 billion of convertibles in two tranches
|
6/16/2006 | BT | Bear Stearns keeps MedImmune at outperform
|
6/15/2006 | BT | MedImmune, NIH begin enrollment in phase 1 study of bird flu vaccine
|
6/2/2006 | BT | Bear Stearns cautions on MedImmune
|
5/25/2006 | BT | MedImmune authorizes $500 million stock repurchase program
|
5/17/2006 | BT | MedImmune at outperform by Bear Stearns
|
5/4/2006 | BT | HHS awards more than $1 billion to five pharmaceutical companies to develop flu vaccines
|
5/1/2006 | BT | MedImmune says its investigational vaccine 55% more effective than flu shot
|
4/21/2006 | BT | MedImmune stays at market perform by JMP
|
4/20/2006 | BT | MedImmune says Q1 revenue down slightly, predicts full-year earnings of $0.19-$0.24 per share
|
4/20/2006 | BT | MedImmune to use Elusys Therapeutics' technology to develop infectious disease therapies
|
4/20/2006 | BT | MedImmune at neutral by Merrill
|
4/20/2006 | BT | Market Commentary: MedImmune dives 12%; Cubist gains over 9%; Discovery Labs, Dynavax rise on financing deals
|
4/13/2006 | BT | MedImmune begins dosing of lupus patients in phase 1 trial
|
4/10/2006 | BT | New data indicates MedImmune's Abegrin may offer three-pronged approach to cancer therapy
|
4/10/2006 | BT | Market Commentary: Cougar Biotech goes public via reverse merger, PIPE; Hythiam hammered; Serono sinks by 10%
|
2/3/2006 | BT | MedImmune kept at neutral by Merrill
|
2/3/2006 | BT | MedImmune keeps market perform rating by JMP
|
1/18/2006 | BT | Market Commentary: KV Pharmaceutical stock up on patent ruling; biotech offerings take a back seat to tech market
|
1/18/2006 | CV | Market Commentary: Techs dominate convertibles market; Intel drops outright but expands on a hedged basis, AMD adds
|
12/15/2005 | BT | Bear Stearns maintains MedImmune at peer perform
|
12/15/2005 | BT | MedImmune completes enrollment in Numax trials for respiratory syncytial virus infections
|
12/14/2005 | BT | MedImmune, Biota to collaborate on RSV infection therapies
|
12/13/2005 | BT | Critical discloses extra R&D funding from MedImmune is worth $1 million
|
12/12/2005 | BT | Merrill says MedImmune still neutral
|
12/12/2005 | BT | Market Commentary: MedImmune up on flu drug data; Merck stock off on Vioxx mistrial; Encysive falls on Myogen's gain
|
12/12/2005 | CV | Market Commentary: Intel launches $1.4 billion convertible offering; Omnicare to price; MedImmune edges up
|
12/12/2005 | BT | MedImmune says phase 3 data shows refrigerator-stable FluMist more effective than injectable vaccine
|
12/8/2005 | BT | MedImmune signs licensing deal with Burnham to develop cancer therapies
|
12/7/2005 | BT | MedImmune obtains patents from Mount Sinai School of Medicine
|
11/15/2005 | BT | Market Commentary: Allergan bid a wrinkle in Medicis merger with Inamed; Biovail off on spinoff plan; SkyePharma up
|
11/15/2005 | CV | Market Commentary: Ford, GM, oil and gas, airlines down; EDO shows up in the gray; Pantry, C&D, E*Trade deals ahead
|
11/8/2005 | BT | William Blair initiates MedImmune coverage at outperform
|
11/7/2005 | BT | Merrill Lynch keeps MedImmune at neutral
|
10/28/2005 | BT | Market Commentary: Accentia drops on IPO debut; Point Therapeutics up on deal delay; Myriad Genetics falls
|
10/21/2005 | BT | Merrill Lynch maintains MedImmune at neutral
|
10/21/2005 | BT | JMP reiterates MedImmune at market perform
|
10/20/2005 | BT | MedImmune, Avidia enter development, licensing deal on anti-cancer products
|
10/10/2005 | BT | Market Commentary: Holiday makes for thin market; Gilead, niche flu drug names go higher; Human Genome lower yet
|
9/28/2005 | BT | Market Commentary: Panacos, SkyePharma add to deal slate; Incyte, Endo drop on news; Electro-Optic rejigs talk, syndicate
|
9/23/2005 | BT | MedImmune initiated by JMP at market perform
|
9/14/2005 | BT | MedImmune to acquire Cellective Therapeutics
|
9/7/2005 | BT | Mature U.S. biotechs have stronger credit than industrials but weaker than Big Pharma, S&P says
|
9/1/2005 | BT | Market Commentary: Chiron shares, convertibles gain on Novartis bid; Par Pharma up 1%; Cephalon up 5%, Abgenix up 9%
|
9/1/2005 | BT | MedImmune upped by Thomas Weisel to outperform
|
9/1/2005 | BT | MedImmune maintained by Merrill Lynch at neutral
|
8/31/2005 | BT | Market Commentary: MedImmune shoots up over 10%; Chiron little changed; Glaxo gains on U.S. flu shot OK; Oscient flat
|
7/15/2005 | BT | Market Commentary: Accentia IPO pushed back; Keryx zooms; Rigel off; Adherex gets big partner; Abgenix seen in play
|
10/12/2004 | CV | Market Commentary: Apex Silver hovers around par; Amkor firms as bids hit; NPS Pharma, biotechs suffer
|
10/5/2004 | CV | Market Commentary: General Mills issue rises; Chiron, Henry Schein fall on flu scare but MedImmune gains
|
4/30/2004 | CV | S&P rates MedImmune converts BBB
|
2/3/2004 | CV | Goldman Sachs prices $10 million 4.875% notes exchangeable for MedImmune
|
12/16/2003 | CV | Market Commentary: Four deals to price after the close Tuesday; Mentor adds $125 million overnighter
|
10/17/2003 | CV | Market Commentary: XL holds up against stock slide on warning, boost to reserves; new Getronics euro issue zooms
|
7/11/2003 | CV | Market Commentary: Charter deal emerges as junk bond to fund tender for its convertibles, which climb further
|
7/10/2003 | CV | New Issue: MedImmune $500 million convertibles yield 1.0%, up 75%
|
7/10/2003 | CV | Market Commentary: CMS ponies up more yield; MedImmune repriced at 95; buzz emerges of Charter deal
|
7/9/2003 | CV | MedImmune $500 million convertible talked at 0.5-1.0% yield, up 75%
|
7/9/2003 | CV | Market Commentary: CMS deal revived with wider yield talk, joining TXU after close as power issues heat up
|
1/30/2003 | CV | Market Commentary: Micron trading lighter as outright buyers hold on; several drug issues gain
|
9/12/2002 | CV | Market Commentary: Market bolstered by tightening credit spreads as stocks decline
|
7/10/2002 | CV | Market Commentary: Stock plunge, earnings worries sideline players, pressure prices
|
4/10/2002 | CV | Market Commentary: Duane Reade brings new deal in new structure; Biotechs, drugs higher on short covering
|
4/5/2002 | CV | Market Commentary: Adelphia gains on hiring advisors; Getty Images soars on EPS revision; Genentech falls
|
12/7/2001 | CV | Market Commentary: Convertible market slides as stock enthusiasm withers, no new deals
|
12/4/2001 | CV | Market Commentary: Convertible market moves higher, gets spate of new deals lineup
|
12/3/2001 | CV | Convertible market pulls back modestly as stocks lose on Enron bankruptcy
|